Is Tisotumab vedotin-tftv included in medical insurance?

Tisotumab vedotin-tftv is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after chemotherapy. This indication has received accelerated approval based on tumor response rate and durability of response. Continued approval of this indication may be contingent on verification and description of clinical benefit in confirmatory trials. Vitin-Tisotuzumab is available as an injectable 40 mg lyophilized cake or powder in single-dose vials for reconstitution.

Patients should follow the prescribing information recommendations before using Vistin-tisotuzumab to reduce the risk of ocular adverse reactions. Perform ophthalmic examinations under physician supervision, including visual acuity and slit lamp examination at baseline, before each dose and as clinically indicated. The initial prescription and all updates of any corticosteroid medication should be made only after examination with a slit lamp. Place the first drop in each eye before each infusion. Instruct patients to continue using prescribed eye drops in each eye for 72 hours after each infusion. Topical ocular vasoconstrictor drops may be administered in each eye immediately prior to each infusion, or a cooling eye patch may be used during Vistin-tisolutumab infusion. Instruct patients to use topical lubricating eye drops during treatment and for 30 days after the last dose of Vitin-Tisotuzumab.

Vitin-TisotumabThe original drug has not yet been marketed in China, so it cannot be included in medical insurance. The original drugs marketed overseas are very expensive. The price of each box of 40 mg/vial may be around RMB 90,000 (the price may fluctuate due to the exchange rate). Currently, there is no generic version of Vitin-Tisotuzumab on the market. For more drug information and specific prices, please consult the medical consultant of the drug.